SCHEMBL23577857

SCHEMBL23577857

CCOC(=O)c1cc2c(cc1Br)n(C)c(=O)c(=O)n2C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.56
▸ KDM4E B2RXH2 6/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ ALDH1A1 P00352 8/20 0.50
▸ MAPT P10636 4/20 0.50
▸ GAA P10253 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ GLA P06280 1/20 0.46
▸ BAZ2B Q9UIF8 1/20 0.46
▸ BAZ2A Q9UIF9 1/20 0.46
▸ LMNA P02545 2/20 0.44
▸ TSHR P16473 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAOB P27338 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183958 1.00 KMT2A (0.56) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL26119918 0.92 KMT2A (0.55) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL30623227 0.92 KMT2A (0.55) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL23578026 0.86 KMT2A (0.50) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL30036547 0.84 KMT2A (0.48) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL23577820 0.84 KMT2A (0.48) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL23577644 0.84 KMT2A (0.48) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL30183966 0.84 KDM4E (0.50) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL23590633 0.84 KDM4E (0.50) KMT2AKDM4ENPSR1RXFP1ALDH1A1
SCHEMBL26123056 0.82 KMT2A (0.46) KMT2AKDM4ENPSR1RXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 — — EP disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 — — CN disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 — — US disclosed
CN-115605476-A Substituted tricyclic compounds 鲁宾有限公司(IN) 2023-01-13 — — CN disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 — — EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 KMT2A 4266/4885KDM4E 4661/4885NPSR1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback